Peru presents distinct medical challenges determined by altitude, mosquito-borne disease zones, and variable sanitation infrastructure. Travelers encounter three geographic health zones: coastal desert where Lima sits at sea level, highlands beginning above 2,400 meters where Cusco stands at 3,399 meters and Puno at 3,827 meters near Lake Titicaca, and lowland rainforest regions including Iquitos and Tambopata National Reserve below 500 meters. Each zone requires different preparation. The Pan American Health Organization documented that altitude illness affects approximately 25 percent of travelers arriving directly to Cusco by air from sea level, while malaria transmission occurs exclusively in jungle departments of Loreto, Madre de Dios, Amazonas, San Martín, Junín, and Ucayali below 2,000 meters elevation. Yellow fever transmission zones cover all Amazon basin regions including access routes to Manu National Park and Pacaya-Samiria National Reserve.
Altitude physiology dominates health planning for Andes travel. Acute mountain sickness symptoms begin when atmospheric oxygen drops below levels the body maintains at sea level. At Cusco's 3,399 meters, barometric pressure delivers only 68 percent of sea-level oxygen. At Huascarán peak elevation of 6,768 meters in Cordillera Blanca, oxygen availability falls to 44 percent. The Lake Louise Scoring System defines acute mountain sickness as headache plus one of nausea, fatigue, dizziness, or sleep difficulty, with symptoms typically emerging 6 to 12 hours after ascent. A 2018 study in High Altitude Medicine & Biology tracking 305 travelers flying directly to Cusco found symptom incidence of 43 percent on day one, declining to 22 percent by day three. Gradual ascent reduces incidence, but commercial flight patterns eliminate this option for most visitors. Acetazolamide 125 milligrams twice daily beginning one day before ascent reduces acute mountain sickness incidence by approximately 50 percent according to meta-analysis published in BMJ 2017, but requires physician prescription and carries side effects including increased urination, finger tingling, and taste alterations. The medication works by inducing metabolic acidosis that stimulates breathing, not by treating symptoms after they appear.
High-altitude cerebral edema and high-altitude pulmonary edema represent life-threatening progressions occurring in approximately 1 to 2 percent of travelers above 3,000 meters. Cerebral edema presents with ataxia, altered consciousness, or severe headache unresponsive to standard analgesics. Pulmonary edema manifests as breathlessness at rest, cough with pink frothy sputum, or cyanosis. Both conditions require immediate descent, measured in hundreds of vertical meters, as primary treatment. Medical facilities in Cusco, Arequipa, and Huaraz can provide supplemental oxygen and hyperbaric chamber treatment, but evacuation to lower altitude remains definitive management. Dexamethasone 8 milligrams initially treats cerebral edema acutely. Nifedipine 30 milligrams extended-release treats pulmonary edema when descent is delayed. These represent emergency bridge therapy, not prevention or definitive treatment. Travelers with cardiac conditions, sickle cell trait, or pulmonary hypertension face elevated risk and require physician consultation before booking Andes travel.
Yellow fever vaccination carries legal and medical dimensions for Peru travel. The Peruvian Ministry of Health requires proof of yellow fever vaccination for travelers entering Amazon regions including Iquitos, Puerto Maldonado gateway to Tambopata, and Manu National Park access points. The vaccine contains live attenuated virus and requires administration at least 10 days before travel to establish immunity. A single dose provides lifelong protection according to World Health Organization guidance issued in 2016, though some countries including Peru officially still reference older ten-year validity for entry purposes. The vaccine certificate remains valid indefinitely per WHO position, but travelers should verify current Peruvian entry requirements through official government channels. Vaccination is contraindicated for people with thymus disorders, immunocompromised status, egg allergy, or age over 60 years with no previous yellow fever exposure due to elevated adverse event risk. These travelers require physician evaluation to determine whether disease risk in their specific itinerary justifies vaccination or whether a medical waiver letter suffices for entry.
Malaria prophylaxis decisions depend on precise itinerary details. Plasmodium vivax accounts for 70 to 80 percent of Peruvian malaria cases, with Plasmodium falciparum comprising most remaining cases in Loreto department. The Centers for Disease Control designates all Amazon basin areas below 2,000 meters as malaria transmission zones, with highest risk in Loreto and Madre de Dios departments. No malaria transmission occurs in Lima, coastal cities, Cusco, Machu Picchu, Lake Titicaca, or highlands above 2,000 meters. Atovaquone-proguanil taken daily starting two days before entry, during exposure, and seven days after leaving transmission zones provides highly effective prophylaxis with favorable side effect profile but costs approximately 8 to 12 US dollars per day. Doxycycline 100 milligrams daily costs substantially less at approximately 0.50 to 2 US dollars per day but causes photosensitivity requiring sun protection and should not be used by pregnant women or children under eight years. Mefloquine taken weekly remains effective but carries neuropsychiatric side effects in approximately 10 to 25 percent of users. Chloroquine alone no longer provides adequate protection against Peruvian P. falciparum due to documented resistance. Travelers spending only brief daylight hours in jungle areas may choose insect repellent and protective clothing without chemoprophylaxis after physician consultation, but overnight stays in lodges near Tambopata River or multi-day excursions in Pacaya-Samiria National Reserve warrant prophylaxis consideration.
Dengue, chikungunya, and Zika transmission occurs in same mosquito habitats as malaria, carried by Aedes aegypti mosquitoes that bite during daylight hours. Peru reported 54,000 dengue cases in 2023 according to Ministry of Health surveillance data, with transmission in Lima's peripheral districts, Amazon regions, and northern coastal cities including Piura and Chiclayo. No vaccine is available for travelers without previous dengue infection, and no prophylactic medication exists for any of these three viruses. Prevention relies entirely on mosquito bite avoidance using DEET concentrations of 25 to 35 percent on exposed skin, permethrin treatment of clothing and bed nets, and long sleeves and pants during dawn and dusk peak biting times. Zika poses pregnancy risk due to documented association with microcephaly, and pregnant women should consult physicians before traveling to transmission zones. Dengue presents particular risk on second infection with different serotype due to antibody-dependent enhancement increasing severe disease probability to approximately 2 to 4 percent in secondary infections versus 0.5 percent in primary infections.
Traveler's diarrhea affects 30 to 70 percent of international visitors to Peru, with highest rates in Amazon regions and lowest rates in international hotels using treated water. The primary cause is enterotoxigenic Escherichia coli, followed by Campylobacter, Shigella, and Salmonella species. Norovirus causes approximately 10 percent of cases. Prevention centers on food and water precautions including bottled water, avoidance of ice from unknown sources, and fully cooked food served hot. Raw vegetables washed in potentially contaminated water carry risk, as does fruit the traveler did not peel personally. Ceviche prepared with contaminated water or held at inadequate temperatures presents documented risk despite citrus juice "cooking" process, which denatures protein but does not eliminate all pathogens. Most cases resolve within three to five days without treatment. Loperamide controls symptoms but should not be used when fever or bloody stool indicates invasive pathogen. Azithromycin 500 milligrams single dose or 1,000 milligrams single dose provides effective treatment for bacterial causes and shortens duration by approximately one to two days. Travelers should carry prescription antibiotic for self-treatment of moderate to severe cases, defined as three or more loose stools in eight hours with accompanying symptoms interfering with planned activities.